Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2011 Apr;82(2):211-6.
doi: 10.3109/17453674.2011.566141. Epub 2011 Mar 24.

Results of the Scandinavian Sarcoma Group XIV Protocol for Classical Osteosarcoma: 63 Patients With a Minimum Follow-Up of 4 Years

Free PMC article
Comparative Study

Results of the Scandinavian Sarcoma Group XIV Protocol for Classical Osteosarcoma: 63 Patients With a Minimum Follow-Up of 4 Years

Sigbjørn Smeland et al. Acta Orthop. .
Free PMC article


Background and purpose: The Scandinavian Sarcoma Group (SSG) XIV protocol is based on experience from previous SSG trials and other osteosarcoma intergroup trials, and has been considered the best standard of care for patients with extremity localized, non-metastatic osteosarcoma. We analyzed the outcome in 63 consecutive patients. Patients and methods From 2001 through 2005, 63 patients recruited from centers in Sweden, Norway, and Finland were included. They received preoperative chemotherapy consisting of 2 cycles of paired methotrexate (12 g/m²), cisplatin (90 mg/m²), and doxorubicin (75 mg/m²). 3 cycles were administered postoperatively, and poor histological responders were given 3 additional cycles of ifosfamide (10-12 g/m²) as a salvage strategy.

Results: With a median follow-up of 77 months for survivors, the estimated metastasis-free and sarcoma-related survival at 5 years was 70% and 76%, respectively. 53 patients were treated with limb salvage surgery or rotationplasty and 2 patients experienced a local recurrence. 3 toxic deaths were recorded, all related to acute toxicity from chemotherapy. The 5-year metastasis-free survival of poor histological responders receiving add-on treatment with ifosfamide was 47%, as compared to 89% for good histological responders.

Interpretation: Outcome from the SSG XIV protocol compares favorably with the results of previous SSG trials and other published osteosarcoma trials. However, salvage therapy given to poor responders did not improve outcome to a similar degree as for good responders. In a multi-institutional setting, more than four-fifths of the patients were operated with limb salvage surgery or rotationplasty, with few local recurrences.


Figure 1.
Figure 1.
Outline of treatment in the SSG XIV protocol.
Figure 2.
Figure 2.
Sarcoma-related (red) and metastasis-free (green) survival (n = 63).

Similar articles

See all similar articles

Cited by 17 articles

See all "Cited by" articles


    1. American Society of Clinical Oncology Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol. 1994;12:2471–508. - PubMed
    1. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M, Campanacci M. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico Rizzoli according to the istituto orotpedico Rizzoli/osteosarcoma-2 protocol: an update report. J Clin Oncol. 2000;18:4016–27. - PubMed
    1. Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F, Serra M, Briccoli A, Balladelli A, Picci P. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a-27-year experience in a single institution. J Surg Oncol. 2007;96:118–23. - PubMed
    1. Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, Brach del Prever A, Gherlinozoni F, Mercuri M, Monti C. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Cancer. 1993;72:3227–38. - PubMed
    1. Bielack S, Erttmann R, Kempf-Bielack B, Winkler K. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer. 1996;32:1652–60. - PubMed

Publication types

MeSH terms